Japan's Takeda has announced the completed acquisition of Ariad Pharmaceuticals, for $5.2 billion -- $24 per share in cash.
After Takeda made several offers, the purchase was made at a 75 percent premium over Massachusetts-based Ariad's previous closing stock price.
The acquisition will add Ariad's innovative targeted therapies and R&D capabilities to Takeda's oncology business. Of particular interest to Takeda is the global potential of Ariad's brigatinib, an investigational drug product, which could become a best-in-class ALK inhibitor for non-small cell lung cancer with the potential to achieve peak annual sales of over $1 billion.
Read the press release